Clal Biotechnology Net Income vs. Shares Owned By Insiders

CBI Stock   35.40  0.30  0.84%   
Based on the key profitability measurements obtained from Clal Biotechnology's financial statements, Clal Biotechnology Industries may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Clal Biotechnology's ability to earn profits and add value for shareholders.
For Clal Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Clal Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Clal Biotechnology Industries utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Clal Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Clal Biotechnology Industries over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Clal Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clal Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clal Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Clal Biotechnology Shares Owned By Insiders vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Clal Biotechnology's current stock value. Our valuation model uses many indicators to compare Clal Biotechnology value to that of its competitors to determine the firm's financial worth.
Clal Biotechnology Industries is rated fourth in net income category among its peers. It also is rated fourth in shares owned by insiders category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Clal Biotechnology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Clal Biotechnology's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Clal Shares Owned By Insiders vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Clal Biotechnology

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(89.58 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Clal Biotechnology

Insiders Shares

 = 

Executives Shares

+

Employees

 = 
64.58 %
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.

Clal Shares Owned By Insiders Comparison

Clal Biotechnology is rated third in shares owned by insiders category among its peers.

Clal Biotechnology Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Clal Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Clal Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Clal Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Clal Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. CLAL BIOTECHNOLOGY operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.

Clal Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Clal Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Clal Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Clal Biotechnology's important profitability drivers and their relationship over time.

Use Clal Biotechnology in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Clal Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Clal Biotechnology will appreciate offsetting losses from the drop in the long position's value.

Clal Biotechnology Pair Trading

Clal Biotechnology Industries Pair Trading Analysis

The ability to find closely correlated positions to Clal Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Clal Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Clal Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Clal Biotechnology Industries to buy it.
The correlation of Clal Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Clal Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Clal Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Clal Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Clal Biotechnology position

In addition to having Clal Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Financials ETFs Thematic Idea Now

Financials ETFs
Financials ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Financials ETFs theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Financials ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Clal Stock

To fully project Clal Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Clal Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Clal Biotechnology's income statement, its balance sheet, and the statement of cash flows.
Potential Clal Biotechnology investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Clal Biotechnology investors may work on each financial statement separately, they are all related. The changes in Clal Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Clal Biotechnology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.